BrECADD vs BEACOPP and Health-Related Quality of Life in Advanced-Stage Hodgkin Lymphoma

This secondary analysis of the GHSG HD21 randomized clinical trial evaluates the tolerability and impact of BrECADD vs escalated BEACOPP on health-related quality of life for patients with Hodgkin lymphoma.

Corresponding Author: Justin Ferdinandus, MD, German Hodgkin Study Group, University Hospital of Cologne, Kerpener Str 62, 50937 Köln, Germany (justin.ferdinandus@uk-koeln.de).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.